ISSN:1040-8746    

出版商:OVID    

年代:1996

数据来源: OVID

ISSN:1040-8746    

出版商:OVID    

年代:1996

数据来源: OVID

ISSN:1040-8746    

出版商:OVID    

年代:1996

数据来源: OVID

ISSN:1040-8746    

出版商:OVID    

年代:1996

数据来源: OVID

ISSN:1040-8746    

出版商:OVID    

年代:1996

数据来源: OVID

摘要:

The biologic and clinical heterogeneity of lymphomas represents the major obstacle to their diagnosis. Because histologic analysis, which is the initial diagnostic approach, has been demonstrated to be insufficient in the definition of certain types of lymphomas, molecular and immunologic techniques have been increasingly applied to obtain a precise diagnosis and to establish a correct treatment. Fluorescencein situhybridization, in particular, is a powerful technique with many applications to the study of chromosomal rearrangements. In addition, because of their specificity and sensitivity, molecular techniques provide an important tool in assessing response to treatment, in detecting minimal residual disease, and in understanding the clinical and prognostic significance of the disease.

ISSN:1040-8746    

出版商:OVID    

年代:1996

数据来源: OVID

摘要:

Humanized monoclonal anti-CD20 has impressive activity and radioimmunoconjugates. Targeting the same molecule has led to prolonged remissions in both moderate and myeloablative doses. Idiotype-based vaccination has produced an apparent prolongation in disease-free and overall survival in selected patients with follicular lymphoma. Adoptive cellular therapy is active in the setting of Epstein-Barr virus–induced lymphoma after allogeneic bone marrow transplantation. Improvements in each of these developments are readily in sight.

ISSN:1040-8746    

出版商:OVID    

年代:1996

数据来源: OVID

摘要:

Follicular lymphoma is the most common histological subtype of so-called indolent lymphomas. Despite the high rate of initial response to treatment, these low-grade B-cell non-Hodgkin's lymphomas follow a fluctuating (indolent) clinical course of regression and progression with an overall median survival of 8 to 10 years. Localized disease may be cured by radiotherapy, although in the majority of patients, the disease is already disseminated at the time of presentation. Current therapies include the use of single agents, such as the established drugs chlorambucil or cyclophosphamide, or the newer purine analogues, such as fludarabine. Combination chemotherapy, including the recently developed regimens based on fludarabine, is often advocated in those with more advanced disease or at subsequent recurrences. High-dose myeloablative therapy with autologous support has become a consideration for most patients whom are eligible or suitable for such treatment. Allogeneic transplantation may also be beneficial to a select group. The management of patients with this group of illnesses, however, may be heavily influenced in the future by the emerging immunologically oriented therapies,ie, monoclonal antibodies and idiotype vaccination.

ISSN:1040-8746    

出版商:OVID    

年代:1996

数据来源: OVID

摘要:

The proposal from the International Lymphoma Study Group (ILSG) of a new classification for lymphoid neoplasm, known as the Revised European-American Lymphoma (REAL) classification, has been received by clinicians and pathologists with mixed reactions. Numerous letters, editorials, and abstracts have been published in the past year praising and criticizing this proposal. The feasibility as well as the clinical validity of the ILSG proposal has been tested in retrospective studies based on large multicenter trials, and a large multi-institutional effort to prove or disprove the validity of the REAL classification was undertaken by the International Non Hodgkin's Lymphoma Classification Project. All these studies seems to confirm the usefulness of the REAL classification. Besides the overall evaluation of the ILSG proposal, the clinical validity of the newly defined entities (eg, mantle cell lymphoma, marginal zone cell lymphoma) has been shown by these and other retrospective studies. However, the main objection of clinicians remains the lack of grouping of lymphoma entities according to their clinical behavior, which we as pathologists believe to be the clinician's task.

ISSN:1040-8746    

出版商:OVID    

年代:1996

数据来源: OVID

ISSN:1040-8746    

出版商:OVID    

年代:1996

数据来源: OVID